150 related articles for article (PubMed ID: 29877179)
21. Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis.
Das A; Mahapatra S; Bandyopadhyay D; Samanta S; Chakraborty S; Philpotts LL; Jahangir E; Roy B
Crit Rev Oncol Hematol; 2021 Jan; 157():103186. PubMed ID: 33309571
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant therapy after nephrectomy for renal cell carcinoma.
Ravaud A
Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():33-36. PubMed ID: 30489037
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: A Concluded Living Systematic Review and Meta-Analysis.
Riaz IB; Siddiqi R; Islam M; He H; Riaz A; Asghar N; Naqvi SAA; Warner JL; Murad MH; Kohli M
JCO Clin Cancer Inform; 2021 May; 5():588-599. PubMed ID: 34043431
[TBL] [Abstract][Full Text] [Related]
24. The merit of tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma: a meta-analysis.
Kourie HR; Bakouny Z; Eid R; Haddad FG; Kattan J
Future Oncol; 2018 Apr; 14(9):829-835. PubMed ID: 29589470
[TBL] [Abstract][Full Text] [Related]
25. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.
Ciccarese C; Iacovelli R; Brunelli M; Massari F; Bimbatti D; Fantinel E; De Marco V; Porcaro AB; Martignoni G; Artibani W; Tortora G
Eur J Cancer; 2017 Sep; 83():237-246. PubMed ID: 28756136
[TBL] [Abstract][Full Text] [Related]
26. The role of vascular epithelial growth factor receptor-tyrosine kinase inhibitors in the treatment of advanced breast cancer: a meta-analysis of 12 randomized controlled trials.
Li J; Huang S; Zheng W; Ding H; Zhang Y; Huang S; Zhang Z; Chen B; Liang Z; He G; Xiao X; Li S; Xu T; Chen X
Curr Med Res Opin; 2013 Dec; 29(12):1691-9. PubMed ID: 23981081
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?
Mollica V; Rizzo A; Di Nunno V; Santoni M; Cheng L; Lopez-Beltran A; Scarpelli M; Cimadamore A; Montironi R; Massari F
Transl Androl Urol; 2021 Mar; 10(3):1581-1587. PubMed ID: 33850792
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
Ravaud A; Motzer RJ; Pandha HS; George DJ; Pantuck AJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Martini JF; Ramaswamy K; Casey M; Staehler M; Patard JJ;
N Engl J Med; 2016 Dec; 375(23):2246-2254. PubMed ID: 27718781
[TBL] [Abstract][Full Text] [Related]
29. Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database.
Wolff I; May M; Hoschke B; Zigeuner R; Cindolo L; Hutterer G; Schips L; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Feciche B; Truss M; Dalpiaz O; Figenshau RS; Madison K; Sánchez-Chapado M; Santiago Martin MD; Salzano L; Lotrecchiano G; Shariat SF; Hohenfellner M; Waidelich R; Stief C; Miller K; Pahernik S; Brookman-May S;
Eur J Surg Oncol; 2016 May; 42(5):744-50. PubMed ID: 26899942
[TBL] [Abstract][Full Text] [Related]
30. Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.
George DJ; Martini JF; Staehler M; Motzer RJ; Magheli A; Donskov F; Escudier B; Li S; Casey M; Valota O; Laguerre B; Pantuck AJ; Pandha HS; Patel A; Lechuga M; Ravaud A
Clin Cancer Res; 2019 Feb; 25(4):1165-1173. PubMed ID: 30401688
[TBL] [Abstract][Full Text] [Related]
31. Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials.
Roussel E; Verbiest A; Kinget L; Boeckx B; Zucman-Rossi J; Couchy G; Caruso S; Job S; de Reyniès A; De Wever L; Baldewijns M; Van Poppel H; Joniau S; Lambrechts D; Albersen M; Beuselinck B
Clin Genitourin Cancer; 2021 Dec; 19(6):e382-e394. PubMed ID: 34362692
[TBL] [Abstract][Full Text] [Related]
32. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
Motzer RJ; Haas NB; Donskov F; Gross-Goupil M; Varlamov S; Kopyltsov E; Lee JL; Melichar B; Rini BI; Choueiri TK; Zemanova M; Wood LA; Reaume MN; Stenzl A; Chowdhury S; Lim HY; McDermott R; Michael A; Bao W; Carrasco-Alfonso MJ; Aimone P; Voi M; Doehn C; Russo P; Sternberg CN;
J Clin Oncol; 2017 Dec; 35(35):3916-3923. PubMed ID: 28902533
[TBL] [Abstract][Full Text] [Related]
33. [Relationship between treatment-related hypertension and therapeutic efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell carcinoma].
Song Y; Du CX; Zhang W; Sun YK; Yang L; Cui CX; Chi Y; Zhou AP; Wang JW; Sun Y
Zhonghua Zhong Liu Za Zhi; 2016 Sep; 38(9):698-702. PubMed ID: 27647404
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
[TBL] [Abstract][Full Text] [Related]
35. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
Calvo E; Escudier B; Motzer RJ; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Ravaud A; Kim D; Panneerselvam A; Anak O; Figlin RA
Eur J Cancer; 2012 Feb; 48(3):333-9. PubMed ID: 22209391
[TBL] [Abstract][Full Text] [Related]
36. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of EGFR Tyrosine Kinase Inhibitors in the Adjuvant Treatment for Operable Non-small Cell Lung Cancer by a Meta-Analysis.
Huang Q; Li J; Sun Y; Wang R; Cheng X; Chen H
Chest; 2016 Jun; 149(6):1384-92. PubMed ID: 26836897
[TBL] [Abstract][Full Text] [Related]
38. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
Oudard S; Elaidi RT
Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
[TBL] [Abstract][Full Text] [Related]
39. Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy.
Bottiglieri A; Sepe P; Stellato M; Pircher C; Fotia G; Leone AG; Guadalupi V; Claps M; Giannatempo P; Verzoni E; Procopio G
Cancer Manag Res; 2022; 14():3071-3081. PubMed ID: 36275783
[TBL] [Abstract][Full Text] [Related]
40. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients.
Liu B; Ding F; Liu Y; Xiong G; Lin T; He D; Zhang Y; Zhang D; Wei G
Oncotarget; 2016 Oct; 7(41):67661-67673. PubMed ID: 27602778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
